about
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesClassical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.What can the pathologist offer for optimal treatment choice?Positive axillary sentinel lymph node: is axillary dissection always necessary?Comparison of Treatment Outcome Between Invasive Lobular and Ductal Carcinomas in Patients Receiving Partial Breast Irradiation With Intraoperative Electrons.Clinical and pathological assessment of high-risk ductal and lobular breast lesions: What surgeons must know.An international study to increase concordance in Ki67 scoring.DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN).Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology Experience.A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.Ectopic breast tissue as a possible cause of false-positive axillary sentinel lymph node biopsies.Immunohistochemically defined subtypes and outcome in occult breast carcinoma with axillary presentation.Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.How do the ASTRO consensus statement guidelines for the application of accelerated partial breast irradiation fit intraoperative radiotherapy? A retrospective analysis of patients treated at the European Institute of Oncology.Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.Clinicopathological and immunohistochemical study of 30 cases of post-radiation atypical vascular lesion of the breast.High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.Paget's disease as a local recurrence after nipple-sparing mastectomy: clinical presentation, treatment, outcome, and risk factor analysis.Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.Accelerated partial breast irradiation with intraoperative electrons: using GEC-ESTRO recommendations as guidance for patient selection.Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypesPredicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsyMale breast cancerRisk of Locoregional Recurrence in Patients With False-Negative Frozen Section or Close Margins of Retroareolar Specimen in Nipple-Sparing Mastectomy[The stereotaxic core breast biopsy using the Mammotome: an alternative to intraoperative examination]Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary reportHER2-negative (1+) breast cancer with unfavorable prognostic features: to FISH or not to FISH?
P50
Q33892778-37004A14-3730-4094-8934-93BEC847267FQ34315684-0B22560A-090E-4DD2-A9DE-733BCE314611Q35230273-F7F36B8D-B2CB-4304-8F48-8AFF115B688BQ36658463-D66EDEB4-98A4-4BF8-ABD9-F1DD1AEF3007Q37117133-22008441-9352-4A3D-ACCA-C448ED5E9615Q37799936-B418B166-E98B-4CE7-AC56-1CECCC32A2FDQ37947918-7249A562-663A-490F-AAB4-169BA67AB6A9Q38620697-FA12D966-21E9-4D20-B1D5-C6D79B86142EQ38932734-4F84C5B5-C01C-4A27-BE95-2F76A7F512C2Q39037175-C9A9A9EF-A1CF-499C-8A5D-1D356F5F523BQ39201239-88263CAB-F473-4301-A0DF-DD1CFBCE6153Q40835681-C28D7BDF-049F-4101-81CE-D564BEEDFD94Q41040499-6D9E34FF-40F6-4305-BBE0-C58AB5AECCB0Q41500814-F7C8AD5B-7824-494E-BA4D-B9C06C2E09F0Q43062601-1D2FEA14-268B-4C06-BA70-A1A468E508E0Q43120755-383E2D24-46F4-435A-B88E-9C3B65ABBAB4Q44100959-B73A8C4D-EBA6-4353-9B44-A91F89A7A69FQ44376859-C7836587-6C14-41A4-BF76-E19B4241F19EQ44543667-E77BBD68-AF11-47E3-889C-DEB9B791AAF6Q44808662-8B684DA8-D9C6-4412-9C32-B7CAA7C8309AQ44825813-3BD1A15F-A060-4975-811F-3883A01AC8B1Q45030854-13DEA979-5BFD-4C22-945D-20A3BF57556CQ45913858-839CD461-A0B9-4648-AE96-0FC7FF44E265Q46694616-F1C062C1-B0A9-4B7A-BBD4-FED2CB109BB2Q46784173-BF6BDDDC-0D83-4047-B189-47387025264FQ46848022-D1F59FDE-22A9-495F-A719-BB4C650552E5Q50667627-1028D0C1-CAFD-4CBC-A126-33F607482CF0Q50897504-287F4170-094C-4B63-A2CF-0B47086D7F82Q50966859-7F422921-1C62-42B9-B603-03149B70A4EDQ53247398-2F8A555E-3FBB-43D9-9BA3-D064958DCF46Q53756743-D4BFAA09-6CAC-4FF2-82CE-48E46A05308DQ54480785-E05B606B-3F2D-404D-953E-FDE1406C838DQ56779241-7BF59570-1265-497A-B165-A77665DA586EQ56779597-E0669A56-6D09-43FD-86B1-8D4B5069AE50Q57139827-6DCEB025-2FE4-44FF-B2D8-4458211839B2Q57580694-AF83B71B-CFDA-4337-83A3-2F84B6BEF419Q77225426-57CA2383-6DB3-468B-A784-1986C428AEDDQ82324251-CD3972EE-354A-4516-9EFC-D85C86D4539AQ83630736-A94F6900-7669-40FF-ACDA-28BCFF7E56A4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mauro Giuseppe Mastropasqua
@ast
Mauro Giuseppe Mastropasqua
@en
Mauro Giuseppe Mastropasqua
@es
Mauro Giuseppe Mastropasqua
@nl
type
label
Mauro Giuseppe Mastropasqua
@ast
Mauro Giuseppe Mastropasqua
@en
Mauro Giuseppe Mastropasqua
@es
Mauro Giuseppe Mastropasqua
@nl
prefLabel
Mauro Giuseppe Mastropasqua
@ast
Mauro Giuseppe Mastropasqua
@en
Mauro Giuseppe Mastropasqua
@es
Mauro Giuseppe Mastropasqua
@nl
P106
P1153
6603909294
P21
P31
P496
0000-0002-8306-0839